COVID nasal vaccines in the US may be in the near future. MucosalImmunity MedTwitter
The idea is gaining ground among infectious disease experts, and for good reason."The mucosal immune system and the circulatory immune system are separate," said Michael W. Russell, PhD, professor emeritus of microbiology and immunology at the University at Buffalo, New York, who has also written about thein fighting the pandemic."There is some cross talk, but they are largely independent.
The most robust immunity against COVID-19, according to Russell, comes when infection in the mouth and upper respiratory tract results in the secretion of immunoglobulin A antibodies, giving mucosal immunity. But, by following up that shot with a nasal vaccine, mucosal immunity at the entry point of the virus can be achieved.
"It's a single booster, so development will be fast," Musunuri said. It will be tested in those who already had a primary series of COVID vaccines.CoviLiv, a live-attenuated intranasal vaccine, performed well in a phase 1 study, according to J. Robert Coleman, PhD, cofounder and Chief Executive Officer of Codagenix, Farmingdale, New York.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
PolitiFact - Kari Lake says falsely that COVID-19 vaccines are ineffective and dangerous for childrenRepublican gubernatorial candidate Kari Lake said COVID-19 vaccines are dangerous and ineffective for Arizona's children. But pediatricians and vaccine studies say otherwise.
Weiterlesen »
Paxlovid May Cut Your Risk Of Long COVID, New Study ShowsThe research found people who took the treatment experienced fewer long-term symptoms like fatigue or brain fog.
Weiterlesen »
COVID-19 Conspiracies Are a Gateway to Other Conspiracy Theories, Study WarnsThinking that the COVID-19 pandemic is in some way a hoax could serve as a 'gateway' for individuals to engage with more complex conspiracy theories, claim a team of researchers from Ohio State University in the US.
Weiterlesen »
New VA study finds Paxlovid may cut the risk of long COVIDFor those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
Weiterlesen »